AbbVie: Hypotrichosis trials

The registry lists 11 Hypotrichosis studies with AbbVie as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 2 1Phase 3 4Phase 4 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bimatoprost for the Treatment of Eyebrow HypotrichosisCompletedNCT01765764Phase 3Results posted
• An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the EyelashesCompletedNCT01623479Results posted
• Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash ProminenceCompletedNCT01448525Phase 4Results posted
• Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash HypotrichosisCompletedNCT01391286Phase 3Results posted
• Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash HypotrichosisCompletedNCT01391273Phase 3Results posted
• Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean SubjectsCompletedNCT01229423Phase 4Results posted
• Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash ProminenceCompletedNCT01064882Phase 2Results posted
• Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in ChildrenCompletedNCT01023841Phase 4Results posted
• Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash HypotrichosisCompletedNCT00958035Phase 4Results posted
• Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid MarginCompletedNCT00907426Phase 3Results posted
• Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in JapanCompletedNCT02505776